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Abstract
Background: New regimens for intermittent preventive treatment in pregnancy (IPTp) against malaria are needed as the
effectiveness of the standard two-dose sulfadoxine-pyrimethamine (SP) regimen is under threat. Previous trials have shown
that IPTp with monthly SP benefits HIV-positive primi- and secundigravidae, but there is no conclusive evidence of the
possible benefits of this regimen to HIV-negative women, or to a population comprising of both HIV-positive and –negative
women of different gravidities.
Methods: This study analyzed 484 samples collected at delivery as part of a randomized, partially placebo controlled clinical
trial, conducted in rural Malawi between 2003 and 2007. The study included pregnant women regardless of their gravidity
or HIV-infection status. The participants received SP twice (controls), monthly SP, or monthly SP and two doses of
azithromycin (AZI-SP). The main outcome was the prevalence of peripheral Plasmodium falciparum malaria at delivery
diagnosed with a real-time polymerase chain reaction (PCR) assay.
Findings: Overall prevalence of PCR-diagnosed peripheral P. falciparum malaria at delivery was 10.5%. Compared with the
controls, participants in the monthly SP group had a risk ratio (95% CI) of 0.33 (0.17 to 0.64, P,0.001) and those in the AZI-
SP group 0.23 (0.11 to 0.48, P,0.001) for malaria at delivery. When only HIV-negative participants were analyzed, the
corresponding figures were 0.26 (0.12 to 0.57, P,0.001) for women in the monthly SP group, and 0.24 (0.11 to 0.53,
P,0.001) for those in the AZI-SP group.
Conclusions: Our results suggest that increasing the frequency of SP administration during pregnancy improves the efficacy
against malaria at delivery among HIV-negative women, as well as a population consisting of both HIV-positive and –
negative pregnant women of all gravidities, in a setting of relatively low but holoendemic malaria transmission, frequent use
of bed nets and high SP resistance.
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Introduction
Malaria is one of the most important preventable causes of poor
maternal health and adverse birth outcomes [1]. In sub-Saharan
Africa (SSA), an estimated 25 million pregnant women are in
danger of Plasmodium falciparum infections every year [2]. Fortu-
nately, much of the malaria-associated morbidity and mortality
can be prevented by intermittent preventive treatment in
pregnancy (IPTp), and 35 of 45 sub-Saharan African countries
had adopted IPTp with sulfadoxine-pyrimethamine (SP) as a
national policy by the end of 2010 [3]. However, the effectiveness
of the standard two-dose SP IPTp is under threat due to increasing
SP-resistance, declined malaria immunity among women infected
with human immunodeficiency virus (HIV), possibly too long
treatment interval, and difficulties in practical implementation [4–
13]. Thus, new antimalarial regimens for IPTp are needed, but
finding an alternative to SP has proven difficult. Therefore the
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WHO continues to recommend the use of SP IPTp for pregnant
women at risk of P. falciparum in SSA [3]. Increasing the dosing
frequency of SP has been considered as one possibility to improve
the effectiveness of SP IPTp while alternative regimens are being
explored.
At least four trials have tested the efficacy of an IPTp regimen
that contains monthly SP-dosing [14–17]. However, three of these
trials focused on defined risk groups and not an unselected
population of pregnant women, which typically comprises the
actual target group for IPTp [14–16]. A Kenyan and a Malawian
study enrolled participants in their first or second pregnancy
[14,15], and a Zambian sample included only HIV-positive
women [16]. These three trials, in aggregate, suggest that monthly
SP results in less placental and peripheral maternal malaria at
delivery and a higher birth weight among HIV-positive primi- and
secundigravidae [13]. However, there is no conclusive evidence of
the benefits of monthly SP for HIV-negative women, for HIV-
positive multigravidae, or for a population comprising of both
HIV-positive and –negative women of different gravidities.
In our previously reported trial from Malawi we included
pregnant women regardless of their gravidity or HIV-infection
status [17]. A total of 1320 participants were randomized to
receive either two doses of SP (control), monthly SP, or a
combination of monthly SP and two doses of azithromycin (AZI-
SP). Compared with the controls, the trial documented a
significantly lower incidence of both preterm delivery and low
birth weight (LBW) in the AZI-SP, but not in the monthly SP
group. Peripheral malaria prevalence assessed by conventional
microscopy was higher among controls (approximately 5%) than
among women in both intervention groups (approximately 2%),
both around 32 gestational weeks and at delivery. However, these
intergroup differences were statistically significant only around 32
gestational weeks – possibly because microscopic malaria samples
at delivery were available only for 481 individuals who gave birth
at a health facility. Hence, we could not establish if the trial
regimens reduced malaria exposure in late pregnancy, nor
whether the differences in pregnancy outcomes between the
monthly SP and AZI-SP groups were due to an additional
antimalarial effect of azithromycin or other factors.
In a subsequent study, we applied a polymerase chain reaction
(PCR) – based method to diagnose malaria from peripheral blood
samples collected at delivery in the above described trial. With this
more sensitive method, we documented an almost five fold higher
prevalence of P. falciparum parasitaemia than earlier diagnosed
with microscopy [18]. In the current study we used the results of
this PCR-methodology to assess the effect of monthly SP and AZI-
SP treatments on peripheral malaria parasitaemia at delivery in a
population that consisted of both HIV-positive and –negative
participants of all gravidities.
Materials and Methods
Study Design and Outcomes
This study is a secondary analysis of peripheral blood samples
collected at delivery for real-time PCR assay targeting P. falciparum
as part of the Lungwena Antenatal Intervention Study (LAIS),
which has been described in detail elsewhere [17]. Of the 1320
LAIS participants, these blood samples were collected only from
the women who delivered at a local health facility. The LAIS
enrolled both HIV-positive and –negative pregnant women of all
gravidities into a randomized, partially placebo controlled clinical
trial, which was conducted in rural Malawi between 2003 and
2007. The study hypothesis was that preterm delivery and other
adverse pregnancy outcomes could be reduced, and maternal
health improved by intermittent preventive treatment (IPT) of
pregnant women with monthly sulfadoxine-pyrimethamine, alone
or in combination with two doses of azithromycin. The protocol
for LAIS and the CONSORT checklist for this paper are available
as supporting information; see Protocol S1 and Checklist S1.
Ethics Statement
The trial was performed according to Good Clinical Practice
guidelines and the ethical standards of Helsinki Declaration. The
protocol was approved by the College of Medicine Research and
Ethics Committee, University of Malawi, Malawi and the Ethical
Committee of Pirkanmaa Hospital District, Finland. Key details of
the protocol were published at the clinical trial registry of the
National Library of Medicine, Bethesda, Md, USA (http://www.
clinicaltrials.gov, trial identification NCT00131235). Only partic-
ipants who signed or thumb-printed an informed consent form
were enrolled in the study.
Study Site and Participants
The target population of LAIS comprised pregnant women who
came between December 2003 and October 2006 for antenatal
care to Lungwena Health Centre, Mangochi district, southern
Malawi. Malaria is holoendemic at this rural site [19]. Inclusion
criteria for the study were gestational age 14–26 weeks by
ultrasound assessment, felt movements of the fetus, availability for
follow-up, and informed consent. Exclusion criteria included
severe illness, receipt of azithromycin during the current
pregnancy or SP within preceding 28 days, allergy to study drugs,
and any previous serious allergic reaction. In the analyses
presented in the current paper only participants with available
real-time PCR results for P. falciparum malaria at delivery were
included.
Study Interventions and other Medication
Participants in the control group (‘‘control’’) received standard
Malawian antenatal care including IPTp with SP (three tablets
orally, each containing 500 mg sulfadoxine and 25 mg pyrimeth-
amine), and a placebo to azithromycin, both given twice during
pregnancy: at enrollment and between 28th and 34th weeks of
gestation. Participants in the first intervention group (‘‘monthly
SP’’) received otherwise the same treatment, but SP was given
monthly from enrollment until 37 gestational weeks. Participants
in the second intervention group (‘‘AZI-SP’’) received otherwise
the same treatment as the monthly SP group, but instead of
placebo, they received active azithromycin twice (two tablets
orally, each containing 500 mg of azithromycin): at enrollment
visit and between 28th and 34th weeks of gestation. All participants
received ferrous sulphate (200 mg/day) and folic acid (0.25 mg/
day) throughout pregnancy.
Participants diagnosed with malaria at enrollment or at 28–34th
week visit received the normal pre-packed study drugs which
included SP for all study groups. Laboratory-confirmed malaria at
any other point was treated with quinine (two tablets orally three
times a day for seven days, each containing 300 mg of quinine).
SP tablets were purchased from Malawi Central Medical Stores
that were supplied by Pharmanova, Ipca Laboratories Ltd,
F.Hoffmann-La Roche Ltd, and Universal Corporation Kenya
Ltd. Both active azithromycin and its placebo were manufactured
and donated by Pfizer Inc. We did not perform any pharmaco-
logical tests on the study drugs.
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Randomization and Enrollment
A researcher not involved in data collection generated a
randomization code list in blocks of nine. Based on this list, an
individual drug box was pre-packed for each identification
number. The drug box contained appropriate study drugs for
each planned study visit in separate opaque drug envelopes labeled
with identification number and visit information. Individual slips
containing unique identification numbers, but not group alloca-
tion, were sealed in individual opaque randomization envelopes.
The envelopes were grouped into randomization blocks to ensure
similar allocation rates to each group.
At enrollment visit, the research personnel interviewed individ-
uals interested in participating in the study about their socioeco-
nomic status, obstetric history and bed net use, gave pre-test HIV-
counseling, and performed an antenatal and laboratory examina-
tions. Testing for HIV was optional. Eligible individuals signed or
thumb-printed informed consent and picked one randomization
envelope which contained an identification number. A research
assistant not involved in outcome assessment gave the correspond-
ing pre-packed study drugs to the participant under direct
observation.
Follow-up
At follow-up visits (at four-week intervals until 36 completed
gestational weeks and weekly thereafter) the research personnel
conducted an antenatal examination. The participants were
offered post-test HIV counseling and prevention of mother to
child transmission. At the visit during 28th–34th weeks of
gestation, a malaria test was conducted. At each visit, the
participant took the appropriate pre-packed study drugs under
direct observation.
Upon notification of a delivery, a research assistant visited the
delivery site. She collected data on delivery, examined the
newborn and gave her/him nevirapine or placebo based on
maternal HIV status. From participants who delivered at a local
health facility, maternal peripheral venous blood was collected as
thin and thick blood films, and as dried blood spots on filter paper.
Laboratory Procedures
Peripheral blood P. falciparum parasitaemia at delivery was
diagnosed with a P. falciparum lactate dehydrogenase-specific
(pfldh) real-time PCR assay using DNA extracted from dried
blood spots, as previously described [18].
Statistical Methods
Statistical analysis was carried out with Stata 9.2 (StataCorp,
College Station, USA). We estimated risk ratio and risk difference
for comparison of binary end-points at a single time point. To
prevent inflated type I errors due to multiple comparisons, we
began hypothesis testing with global null hypotheses of all three
groups being identical before doing pair-wise comparisons. We
tested the hypotheses with Fisher’s exact test.
The proportion of women with no previous pregnancies was
higher in the control and monthly SP groups than in the AZI-SP
group, and the proportion with peripheral malaria parasitaemia at
enrollment was higher in the control group than in the
intervention groups. As sensitivity analyses, we adjusted for these
two covariates as categorical variables by generalized linear
models and compared the adjusted and main analyses. We
performed tests for interaction between the interventions and HIV
status (those whose status was known), the number of previous
pregnancies (classified as none, and one or more), and bed net use
using the likelihood ratio test, and did analyses stratified by the
same variables.
Results
Participants and Received Treatment
Of the 1320 LAIS participants [17], 484 (36.7%) had dried
blood spots taken at delivery at a local health facility for the real-
time PCR assay targeting P. falciparum, and they formed the study
population (figure 1). They were on average younger, had more
education, were more often primigravida, made more health
centre visits, and received slightly more study drugs than the 836
(63.3%) participants excluded from the current analysis due to
missing PCR-results (table 1). Except for the number of previous
pregnancies and the prevalence of microscopic malaria parasitae-
mia (32.7%, 34.4%, 19.9% were primigravida, and 14.8%, 8.6%,
3.5% had baseline malaria in the in the control, monthly SP and
AZI-SP groups, respectively), the characteristics of the three study
groups were comparable at enrollment.
The mean (standard deviation, SD) number of scheduled SP
treatments received was 2.0 (0.2) in the control, 4.2 (0.9) in the
monthly SP, and 4.1 (0.8) in the AZI-SP group. Women in the
AZI-SP group received a mean (SD) of 2.0 (0.1) azithromycin
doses. The mean number (SD) of quinine doses given at non-
scheduled outpatient visits was 0.04 (0.23) for the control, 0.05
(0.22) for the monthly SP, and 0.02 (0.15) for the AZI-SP group
(P = 0.415). Against the trial protocol some SP-doses were given
also at the non-scheduled visits, but the number of these was very
small and there were no differences between the groups (4
participants each received one additional dose: 1 in control, 2 in
monthly SP and 1 in AZI-SP group).
Study Outcome
The overall prevalence of PCR-diagnosed peripheral P.
falciparum malaria at delivery was 10.5%, with significant
differences between women in the control group and those who
received monthly SP either alone or in combination with
azithromycin (P,0.001, table 2). Compared with the controls,
participants in the monthly SP group had a risk ratio (95%
confidence interval, CI) of 0.33 (0.17 to 0.64, P,0.001) and
absolute risk reduction of 13.7% (6.4 to 21.1%) for malaria at
delivery. For women in the AZI-SP group, the corresponding risk
ratio (RR) was 0.23 (0.11 to 0.48, P,0.001) and risk reduction
15.7% (8.7 to 22.7%).
Ancillary Analyses
Sensitivity analyses, adjusting either for the number of previous
pregnancies or microscopic malaria parasitaemia at enrollment,
gave essentially identical results to those of the unadjusted analysis
(table 2), as did an analysis adjusting simultaneously for these
variables. In the latter analysis, women in the monthly SP group
had a 13.7 percentage point (95% CI 6.4 to 21.1%, P,0.001)
lower prevalence of PCR-positive malaria at delivery than the
participants in the control group. For women in the AZI-SP
group, the corresponding risk reduction was 14.5% (7.7 to 21.4%,
P,0.001).
In a stratified analysis including only HIV-negative participants,
those in the monthly SP group had a RR (95% CI) of 0.26 (0.12 to
0.57, P,0.001) and those in the AZI-SP group 0.24 (0.11 to 0.53,
P,0.001) for PCR-diagnosed malaria at delivery, when compared
with the controls (table 3). Malaria was more prevalent, and the
study interventions were associated with a greater reduction in
malaria prevalence, among participants who were primigravida
than among those who had previous pregnancies (P = 0.009 for
Effect of SP & Azithromycin on Malaria at Delivery
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prevalence), and among women who did not use a bed net the
night before enrollment than among those who used one (P,0.001
for prevalence). There was no significant interaction between these
characteristics and the intervention on the prevalence of PCR-
diagnosed malaria at delivery (P = 0.480 for HIV status at
enrollment, P = 0.259 for the number of previous pregnancies,
and P = 0.820 for bed net use at enrollment).
Discussion
The use of IPT during pregnancy can prevent malaria and the
adverse outcomes it causes to pregnant women and their fetuses in
SSA. In the current analysis we used a sensitive PCR–based
diagnostic method to compare the antimalarial effect of the
standard two-dose SP IPTp regimen with monthly SP, alone or in
combination with two doses of azithromycin. Compared with the
control group, the participants in the monthly SP and AZI-SP
Figure 1. Participant flow in CONSORT recommended format.
doi:10.1371/journal.pone.0041123.g001
Table 1. Baseline characteristics at enrollment.
Characteristic
Sub-
characteristic
Control (SP twice)
N=162
Monthly SP
N=151
AZI-SP
N=171
LAIS participants not included in the
current analysis (all groups
combined)
N=836
Mean (SD) age in years 24 (7) 24 (6) 25 (6) 25 (7)
Number (%) of literate participants 49 (30.3%) 47 (31.1%) 65 (38.0%) 223 (26.7%)
Mean (SD) years of schooling completed 2.5 (2.9) 2.4 (2.9) 2.8 (2.9) 2.0 (2.6)
Mean (SD) height in cm 154.8 (5.9) 154.4 (5.2) 155.0 (5.5) 155.2 (5.5)
Mean (SD) BMI as kg/m2 21.7 (2.1) 21.8 (2.3) 22.1 (2.1) 21.7 (2.2)
Mean (SD) gestational age at enrollment in
weeks
20.3 (3.0) 19.5 (3.2) 19.9 (3.0) 20.2 (3.0)
Number (%) of previous pregnancies
None 53 (32.7%) 52 (34.4%) 34 (19.9%) 167 (20.0%)
One or more 109 (67.3%) 99 (65.6%) 137 (80.1%) 669 (80.0%)
Number (%) of women owning a bed net 123 (75.9%) 107 (70.9%) 130 (76.0%) 608 (72.7%)
Number (%) of women who used bed net the
night before enrollment
104 (64.2%) 88 (58.3%) 100 (58.5%) 505 (60.4%)
Maternal HIV status, number (%)
Positive 18 (11.1%) 19 (12.6%) 23 (13.5%) 101 (12.1%)
Negative 129 (79.6%) 119 (78.8%) 129 (75.4%) 656 (78.5%)
Unknown 15 (9.3%) 13 (8.6%) 19 (11.1%) 79 (9.5%)
Number (%) with microscopic peripheral blood
malaria parasitaemia at enrollment
24 (14.8%) 13 (8.6%) 6 (3.5%) 74* (8.9%)
Mean (SD) blood Hb concentration as g/L 109 (18) 110 (16) 110 (20) 111 (19)
Abbreviations: AZI-SP, intervention group that received monthly SP and two doses of azithromycin; SD, standard deviation; BMI, body mass index; Hb, hemoglobin.
*Denominator is 835 because of one missing malaria result.
doi:10.1371/journal.pone.0041123.t001
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groups had relatively 67% and 77% lower prevalence of PCR-
diagnosed peripheral P. falciparum malaria parasitaemia at delivery,
respectively. In stratified analyses, HIV-negative participants of all
gravidities, primigravidae regardless of their HIV-status, and
women who did not use a bed net at enrollment had significantly
less malaria in both intervention groups than those in the control
group.
The study population was drawn from a trial which used broad
inclusion criteria, random group allocation and blinding of the
outcome assessors [17]. The intervention code was linked to the
malaria results only after the DNA-based diagnostic tests were
completed. The number of participants with available PCR-
results, as well as their baseline characteristics, was similar in the
three study groups, except for differences in the number of
previous pregnancies and the prevalence of malaria parasitaemia.
However, similar differences were seen already in the main study
[17], and adjusted analyses suggested that these did not bias the
results. Confidence interval calculations and hypothesis testing
indicated that the probability of type I error was small. We
therefore believe that the sample findings were reliable and
representative, and that IPTp with monthly SP, with or without
azithromycin, was indeed associated with reduced prevalence of
PCR-diagnosed peripheral P. falciparum malaria parasitaemia at
delivery in the target population from which the sample was
drawn.
A secondary analysis of pooled data from three other clinical
trials from Kenya, Malawi and Zambia suggested that compared
with the two-dose SP regimen, the monthly regimen had a
beneficial effect on malaria prevalence at delivery and birth weight
among HIV-positive pregnant women in their first or second
pregnancy [13]. The previous Malawian study found significantly
lower peripheral malaria at delivery in the monthly SP group also
among HIV-negative primi- and secundigravidae [15]. However,
when this data was pooled with the data of HIV-negative
participants in the Kenyan study, the analysis failed to document
statistical significance [13]. None of these earlier studies addressed
the efficacy of the monthly SP regimen in a representative sample
that contained both HIV-negative women and those with more
than one earlier pregnancy [14–16]. Hence, it has thus far been
uncertain, whether the monthly SP regimen would best be
reserved for some selected risk groups, or it should be given to all
pregnant women in malaria endemic areas [13].
Our results indicate that IPTp with monthly SP can in some
conditions reduce the prevalence of peripheral blood P. falciparum
malaria parasitaemia at delivery in the latter, wider target group,
as well as among HIV-negative women regardless of their
gravidity. This finding is consistent with the results of a recently
reported trial from Mali, which found that IPTp with three doses
of SP is superior to two doses in reducing malaria prevalence at
delivery, LBW and premature delivery among mainly HIV-
negative women of different gravidities [12]. The sample of the
current substudy was not powered to look at more direct health
outcomes, but since also PCR-detectable submicroscopic parasit-
aemias have important consequences to maternal health and birth
outcomes, the observed effect is likely to be beneficial both to the
mother and the newborn [20–22] (Atupele Kapito-Tembo et al,
unpublished results).
Besides the apparently improved efficacy against malaria,
monthly dosing would solve some of the problems associated with
the two-dose SP IPTp. There are concerns that the dosing interval
in the two-dose regimen might be too long even in areas with low
levels of SP resistance, and increasing resistance further shortens
the duration of the post-treatment prophylactic effect [6,12]. This
concerns especially HIV-positive women not taking cotrimoxazole
prophylaxis, who have increased susceptibility to malaria in
pregnancy and reduced efficacy of antimalarial drugs [7,8,13].
Also, many pregnant women receive none or only one dose of SP
despite making several antenatal care visits during the second and
third trimesters [9–11]. One reason for this is the difficulty to
determine the appropriate timing of the doses; monthly SP policy
would simplify the dosing regimen and thus ensure that more
women receive at least two doses of SP [10,11,15,23,24]. Previous
results suggest that also monthly SP, alone and in combination
with azithromycin, is safe to use during the second and third
trimesters of pregnancy [13,17,25,26]. All this, together with the
ease of single-dose administration which can be done under direct
observation at antenatal care visits, and the low price of SP, makes
the monthly SP regimen seem suitable for IPTp until an effective,
safe and feasible alternative for SP has been identified.
However, before adopting a monthly SP IPTp policy, several
issues have to be taken into consideration. The prevalence of
mutations in P. falciparum associated with resistance to SP has
increased in Africa, and is very high among pregnant women in
some parts of Malawi [4,5]. There have been concerns that IPTp
might increase resistance and even cause adverse outcomes, but
the results have so far been contradictory [5,27–31]. Additionally,
local conditions such as malaria prevalence and the level of
acquired malaria immunity among the target group need to be
taken into consideration as they might affect SP IPTp efficacy. In
our study area the level of resistance was high already during the
enrollment between 2003 and 2007: over 80% of the malaria
isolates collected among the LAIS participants at enrollment were
found to express quintuple DNA mutations for SP resistance
(Steven Meshnick et al, unpublished results).
In our previous analysis we found that the combination regimen
of monthly SP and two doses of azithromycin, but not monthly SP
alone, was significantly superior to the standard regimen of two SP
doses in preventing preterm delivery and LBW [17]. Azithromycin
is both a modestly active antimalarial and a potent broad-
spectrum antimicrobial drug, and thus the improved efficacy of the
combination could have been due to either activity [32,33].
However, because the prevalence of microscopic malaria was low,
we were earlier unable to adequately separate the antimalarial and
other possible effects of azithromycin.
In the current analysis, we found that the monthly SP regimen
was associated with statistically significant reductions in PCR-
diagnosed malaria prevalence at delivery both alone, as well as in
combination with azithromycin, and that there were no major
differences between the two intervention regimens in the point-
estimates for the effect size. The results thus suggest that the
decrease in parasitaemia at delivery was mainly caused by the
increased frequency of the SP dosage, while the improvement in
birth outcomes might have been due to some other activity of
azithromycin, independent of its activity against malaria. A
possible explanation for azithromycin’s weak antimalarial effect
in our study is the used dosage. Although 1g dose of azithromycin
given twice several weeks apart is sufficient to cure many RTIs, it
might be suboptimal against P. falciparum malaria [32,33].
Two limitations of our study are that we analyzed the
prevalence of malaria parasitaemia with PCR only at delivery,
and only from peripheral blood. It could be argued that the
difference in parasitaemia at delivery simply reflects the fact that
the last dose in the regimens containing monthly SP was given
nearer to delivery than in the two-dose regimen. Thus we cannot
rule out that the groups might have had comparable malaria
prevalence during pregnancy and that the differences only
developed towards delivery. However, it is unlikely that the
efficacy of SP would have differed during pregnancy, and
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therefore the monthly dosing with shorter treatment intervals is
likely to have been more effective throughout pregnancy. This is
supported by our finding of a comparable effect size in the
prevalence of microscopic malaria parasitaemia at 32 gestational
weeks in the original sample from which the current study
population was drawn [17]. Another limitation is that we did not
perform analyses with PCR of placental blood and did not collect
histological samples of the placenta to diagnose placental malaria.
The microscopic results of placental blood showed no difference
between the groups [17].
In conclusion, our results suggest that increasing the frequency
of SP administration during pregnancy improves efficacy against
malaria at delivery among HIV-negative women as well as a
population consisting of both HIV-positive and –negative preg-
nant women of all gravidities in a setting of relatively low but
holoendemic malaria transmission, frequent use of bed nets and
high SP resistance. However, further research is needed to study
the consequences of the prevention of submicroscopic malaria
infections to maternal and child health, as well as the effect of
different levels of resistance and malaria prevalence on the IPTp
efficacy. We therefore recommend the use of sensitive diagnostic
tools for malaria, such as PCR and placental histology, and the
determination of the level and change of drug resistance and
acquired immunity in future IPTp trials.
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